CL2019003484A1 - Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina. - Google Patents

Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.

Info

Publication number
CL2019003484A1
CL2019003484A1 CL2019003484A CL2019003484A CL2019003484A1 CL 2019003484 A1 CL2019003484 A1 CL 2019003484A1 CL 2019003484 A CL2019003484 A CL 2019003484A CL 2019003484 A CL2019003484 A CL 2019003484A CL 2019003484 A1 CL2019003484 A1 CL 2019003484A1
Authority
CL
Chile
Prior art keywords
melanocytes
hyperactivity
treatment
disorders associated
botulinum neurotoxin
Prior art date
Application number
CL2019003484A
Other languages
English (en)
Spanish (es)
Inventor
Birgitte P S Jacky
Shizazh Z Malik
Joanne Wang
Yi Liu
Amy Brideau-Andersen
Lance E Steward
Linh Q Le
Edward C Hsia
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2019003484A1 publication Critical patent/CL2019003484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
CL2019003484A 2017-05-31 2019-11-28 Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina. CL2019003484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
CL2019003484A1 true CL2019003484A1 (es) 2020-05-15

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003484A CL2019003484A1 (es) 2017-05-31 2019-11-28 Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.

Country Status (16)

Country Link
US (3) US10912823B2 (https=)
EP (1) EP3630298A1 (https=)
JP (1) JP7096845B2 (https=)
KR (1) KR20200011499A (https=)
CN (1) CN110891594A (https=)
AU (1) AU2018277754A1 (https=)
BR (1) BR112019025402A2 (https=)
CA (1) CA3065542A1 (https=)
CL (1) CL2019003484A1 (https=)
CO (1) CO2019014592A2 (https=)
IL (1) IL270986B (https=)
MX (1) MX2019014349A (https=)
PH (1) PH12019502721A1 (https=)
RU (1) RU2019143639A (https=)
WO (1) WO2018222652A1 (https=)
ZA (1) ZA201907916B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120195878A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
CN105683212B (zh) * 2013-08-21 2020-03-17 香港理工大学 高催化活性的基因改造梭菌属神经毒素
WO2016048689A1 (en) * 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
MX2019005833A (es) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
AU2018389104A1 (en) * 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Also Published As

Publication number Publication date
IL270986B (en) 2021-07-29
JP2020522492A (ja) 2020-07-30
US20210162027A1 (en) 2021-06-03
BR112019025402A2 (pt) 2020-06-23
AU2018277754A1 (en) 2020-01-02
RU2019143639A (ru) 2021-06-30
US20230302103A1 (en) 2023-09-28
PH12019502721A1 (en) 2020-10-19
KR20200011499A (ko) 2020-02-03
EP3630298A1 (en) 2020-04-08
US20180344820A1 (en) 2018-12-06
ZA201907916B (en) 2021-05-26
WO2018222652A1 (en) 2018-12-06
CO2019014592A2 (es) 2020-06-09
MX2019014349A (es) 2020-07-28
JP7096845B2 (ja) 2022-07-06
CN110891594A (zh) 2020-03-17
IL270986A (en) 2020-01-30
RU2019143639A3 (https=) 2021-09-06
CA3065542A1 (en) 2018-12-06
US10912823B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
CL2019003484A1 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011966A (es) Compuestos de resorcinol para uso dermatologico.
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2019013657A (es) Metodo cosmetico para reducir las señales dermatologicas de envejecimiento.
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112016025333A2 (pt) agente, produto e uso
MX2018000274A (es) Bacterias oxidantes de amoniaco para el tratamiento del acne.
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2017015292A (es) Composicion para tratar lesiones cerebrales.